Hi ladies,
Hope you're having a good day.
Just came across this article about ibrance
pfizer.com/news/press-relea...
49 months median OS vs 43. It's kind of disappointing compared to the other 2 cdk 4/6 - I remember reading 63 months for one and over 70 for the other.
Ibrance just offers 6 extra months.
Am I reading things right? I'm really surprised.
Lovexxx
Lucie
Unfortunately, this was something known before. I went to Stanford for a second opinion and they also confirmed that while Ibrance and other new treatments only slightly increases OS but it allows for longer time without disease progression improving quality if life. Honestly, I was a bit surprised ....it does not make sense. BUT, new meds and treatment combos are always in the works, so fingers crossed 
Ibrance studies started earlier, there wasn’t a particular selection. When studies on Ribociclib and Abemaciclib started, reserhers could read Ibrance results and select patients maybe excluding the categories who had poor results on Ibrance. That’s what I read but it’s just a hypothesis, but could partly explain the difference of OS between the three CDK 4/6. Anyway, these treatments aren’t resolutive, but they have opened a new perspective for future developments! Let’s think positive
Hi Guys- full disclosure I’m a retired pfizer oncology sales rep and recently moved on from 18 months on Ibrance and had hoped for longer… but this is actually pretty great news! This is is real world data…that means that anyone put on Ibrance first line could get monitored on this trial which started after Ibrance got FDA approval and became available to all ER+ MBC pts.… and that means some really sick people with some really bad features might have been enrolled… where as in the clinical trials they weed out and only allow very specific pts in… you know how we all worry about being excluded or having to come off a clinical trial cuz we just don’t fit the exact criteria… well in this study they allowed all those pts with features that might have excluded from a phase 3 clinical trial… this study is just a monitoring trial…. As in it doesn’t have a comparator arm.. I don’t believe that the other CDK4-6 inhibitors have been around long enough yet to to release a study of real world data… so we can’t compare the OS data of this study to their clinical trial data because like Ibrance’s clinical trials they were both able to exclude pts with undesirable features… so it isn’t an apples to apples comparison. This is actually a pretty substantial jump in PFS and OS( 25% and 30% respectively) and so just adds to the growing body of evidence that proves that standard of care for first line therapy should include a CDK-4 6 inhibitor.
Bettybuckets, thank you for sharing this info . I sell real estate but always wished i had been a pharmaceutical rep ! Last year I asked my oncologist if kisquali is a better drug since the pfs and os are longer compared to Ibrance and she told me what you just explained (but not as clearly as you just did ).
Wow!!! Fantastic, *fascinating* insight! Thank you *so much*!!
I just started my 30th cycle of Ibrance and had my fulvestrant injections this am as well. My oncology nurse practitioner told me that she saw a patient yesterday that has been on Ibrance for 7 years . It seems like the cdk/4-6 classification of drugs has really helped er/pr + MBC patients live longer and have decent QOL. I am trying to stay hopeful for all of us that new treatments are in the works .
My oncologist said Ibrance was only approved for use in 2017 so we don’t know beyond 5 years
I think the patient who my oncology nurse practitioner was referring to must have been in a clinical trial and is still on Ibrance - either way 7 years was great to hear !
I was similarly explained Ibrance trails were stopped in a shorter timeframe thank Ribo and Verzenio, there also have not been any head to head comparison trials. I thought about switching from Palbo to Ribo, thinking it’s a stronger blocker they have better data. I’m a data type person so that gives me comfort.
From Dr. Google: When was Ibrance first used?
In February 2015, the Food and Drug Administration (FDA) approved palbociclib (Ibrance, Pfizer), in combination with letrozole, as initial endocrine-based therapy for postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer.
Thankyou very much.
On further reading, Ibrance was granted "accelerated approval" in 2015, "expanded approval" in 2016, and "regular approval" in 2017. Sheesh!! It did go on the market in 2015. Too much Googling for one day!
Thankyou, that explains it! The hospital I go to didn’t start using it until 2017 but obviously it came out before. Thanks for all your hard work xx
Thanks! And, at the time, it was approved only for people dx'd within 6 months, I believe. At the time, my doc said to me "you're very lucky to be within that window, I have many patients this could help but I cannot yet put them on the drug".
Everyone is a bit different. I just passed my sixth year on Ibrance with Fulvestrant.
The study lengths might vary by country? I've been on Ibrance for a bit over seven years, US based, approved in 2015 (i.e. I started it right after).
Thanks,I’m in UK. That’s very impressive to be on Ibrance for 7 years and I’m pleased to have learned that.I am very interested to know where you have the cancer if you want to tell me. I have been on Ibrance / letrazole combo 1 year for de novo bc metastases to lymph nodes in chest and denosumab injection 6 months for small spread to spine. I have some regression on these. Thankyou
I’m with you! On Ibrance 125 and Fulvestrant for 16 months now. Got to NED with this 1st line combo in March so hope to continue being in remission for a good while before having to make a change.
I like to live in the moment and appreciate where I am which is 4 ½ years on Ibrance and anastrozole and feeling pretty good. Our options after this regimen are growing. Thanks to Bettybuckets, I have a better understanding of how the trials work. ❤️🧜♀️
Also there are many additional things we can do to help boost our immune system, and improve outcomes (nutrition , exercise, supplements, socialising, finding a purpose, complementary therapies, spiritual practice). No single one is a 100% 'cure' but there is ample evidence they improve quality of life and support the efficacy of the drugs.
I am on cycle 53 of Ibrance, that is 4 plus years and doing well; just turned 74. I don't read the "data" very often but find I have to go back and re-read to get clarity. Usually a second or 3rd reading makes me feel better! Thanks for other replies also.
Not to worry. In 5yrs. they will have come up with a new drug. Also, you can always try the ;sister' Verzenio. It has been very good for me. Just in my 3rd session though.
Cheers, June S,
I asked my doctor what would be next after Ibrance...on it 38 months. She said new things every day...will go there when we need to and not before!
I got to NED after 15 months on Ibrance & Fulvestrant. Had nodule and pleural effusion in left lung—GONE! Onc said when it rears its ugly head again it will be zapped wherever it is and he will start me on Verzenio so I kind of know the plan. Hopefully I will be in remission long enough to see many other combos become available which is so encouraging!
Please give me the name of the article and where I can find it. I see the reference to it but not its name or source. Thanks
Oh I see, I see it wasa link. Thanks
when i read research, and consider western medication, i look to the benefits and how they outweigh the costs. i welcome the additional PFS and OS from Ibrance. i am on the same first line of treatment that began in Aug 2015. further, this mind- body has been stable and NEAD since Mar 2106.
Ibrance 
Ibrance and the tongue
Ibrance
Ibrance
